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Abstract
Background: The atypical antipsychotic drug aripiprazole binds with high affinity to a number of G protein coupled receptors, 
including dopamine D2 receptors, where its degree of efficacy as a partial agonist remains controversial.
Methods: We examined the properties of aripiprazole at D2-like autoreceptors by monitoring the changes of dopamine 
synthesis in adult rat brain striatal minces incubated ex vivo. The effects of the dopaminergic tone on the properties of 
aripiprazole were assayed by comparing a basal condition (2 mM K+, low dopaminergic tone) and a stimulated condition 
(15 mM K+, where dopamine release mimics a relatively higher dopaminergic tone). We also used 2 reference compounds: 
quinpirole showed a clear agonistic activity and preclamol (S-(-)-PPP) showed partial agonism under both basal and 
stimulated conditions.
Results: Aripiprazole under the basal condition acted as an agonist at D2-like autoreceptors and fully activated them at about 
10 nM, inhibiting dopamine synthesis similarly to quinpirole. Higher concentrations of aripiprazole had effects not restricted 
to D2-like autoreceptor activation. Under the stimulated (15 mM K
+) condition, nanomolar concentrations of aripiprazole 
failed to decrease dopamine synthesis but could totally block the effect of quinpirole.
Conclusions: Under high dopaminergic tone, aripiprazole acts as a D2-like autoreceptor antagonist rather than as an agonist. 
These data show that, ex vivo, alteration of dopaminergic tone by depolarization affects the actions of aripiprazole on D2-like 
autoreceptors. Such unusual effects were not seen with the typical partial agonist preclamol and are consistent with the 
hypothesis that aripiprazole is a functionally selective D2R ligand.
Keywords: schizophrenia, striatum, intrinsic efficacy, intrinsic activity, GPCR
Introduction
Aripiprazole (ARI; OPC-14597), a derivative of a dopamine (DA) 
autoreceptor agonist OPC-4392, is considered as an effective 
antipsychotic drug with a controversial mechanism of action 
(Mailman, 2007; Mailman and Murphy, 2010). Compared with 
other antipsychotics, ARI has a safe and tolerable side-effect 
profile that includes low potential for extrapyramidal symptoms, 
weight gain, prolactin elevation, and sedation (Leucht et al., 2009). 
Because of its clinical efficacy and little chance to provoke adverse 
events during the therapeutic process, a lot of research has been 
addressed to explain the unique properties of ARI as well as to 
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supply a solid basis for developing a new generation of antipsy-
chotics. According to these observations, ARI seems to be a DA D2 
receptor partial agonist with high affinity binding to many G pro-
tein coupled receptors, such as serotonergic, adrenergic, and his-
taminergic receptors (Shapiro et al., 2003). It is believed that the 
partial agonism of ARI at D2 receptor would be the main explana-
tion for its unique clinical profile. Nevertheless, partial agonism 
at serotonin (5-HT) receptors 5-HT1A and 5-HT2C and antagonism 
at 5-HT2A may contribute to its special characteristics (Lawler 
et al., 1999; Shapiro et al., 2003; Bortolozzi et al., 2007). In addition, 
increasing evidence makes it difficult to consider ARI as a sim-
ple D2 partial agonist. Thus, the functional action of ARI at DA D2 
receptors may vary among agonist, partial agonist, or antagonist 
depending upon the assessment system, the cell type selected, 
the function examined, the receptor density, the receptor reserve 
levels (Shapiro et al., 2003, Tadori et al., 2009), D2-D3 heteromeri-
zation (Maggio and Millan, 2009), or the surrounding environ-
ment, which likely differs between brain regions (Koener et al., 
2012). The concept of “functional selectivity” that was proposed 
by Lawler et al. (1999) and well addressed by Urban et al. (2007a) 
to interpret the unique behavior of ARI at D2 receptor seems more 
appropriate than simply considering it as a partial agonist.
Kikuchi et  al. (1995) demonstrated the apparent inconsist-
ency of the behavior of ARI at D2 presynaptic autoreceptors and 
D2 postsynaptic receptors, as it seems to perform as an agonist 
at the former while as an antagonist at the latter. The antago-
nism at postsynaptic D2 receptors has been accepted as a way 
of controlling symptoms of schizophrenia, based on the thera-
peutic effect of conventional antipsychotics in treating positive 
symptoms (Mailman and Murphy, 2010). Additionally, activation 
of D2 autoreceptors might also be beneficial for the treatment of 
some symptoms of schizophrenia (Tamminga, 2002), although 
this agonistic effect of ARI is controversial, as it appears to be 
quite dependent upon the surrounding conditions like recep-
tor density or receptor reserve (Tadori et  al., 2011a, 2011b). 
Most of these reports were done in cell lines transfected with 
a high density of D2S receptor, which is the main subtype of the 
D2 autoreceptors (Usiello et  al., 2000). Also, the dopaminergic 
tone in the surrounding milieu has proved to be very important 
for evidencing the agonistic profile of ARI (Iñiguez et al., 2008). 
The functional actions of ARI at cloned human D2-DA receptors 
show a range of actions (agonism, partial agonism, antagonism) 
depending upon the cell type and function examined (Lawler 
et  al., 1999; Shapiro et  al., 2003). Thus, more reliable evidence 
from noncloned, native receptor systems is needed to shed light 
on ARI actions in vivo.
In our laboratory, we have developed a method that allows 
measuring the DA synthesized in dopaminergic neuron termi-
nals in a relatively short period of time (Gonzalez-Sepulveda 
et al., 2013). Because this is a presynaptic response, it is regulated 
by the D2-like autoreceptors located on dopaminergic terminals. 
Thus, the stimulation or blockade of D2 autoreceptors will be 
reflected as changes in DA synthesis. By using this method in 
the present study, we monitored the direct functional effect of 
ARI at D2-like autoreceptors under a low or relatively higher 
dopaminergic tone elicited by modifying K+ concentrations.
Materials and Methods
Materials
ARI was kindly provided by Otsuka Pharmaceutical Co. Ltd. 
(Tokyo, Japan). (-)-Quinpirole hydrochloride (QUIN) and (S)-
(-)-sulpiride were from Tocris Bioscience (Minneapolis, MN). 
Opti-Phase Hisafe-3 liquid scintillation cocktail and [3, 5 - 3H]-L-
tyrosine (40–60 Ci/mmol) were supplied by PerkinElmer Wallac 
(Turku, Finland). ARI and sulpiride were dissolved in ethanol at 
10 mM and diluted with water and QUIN was dissolved in water. 
[3, 5- 3H]-L-tyrosine was purified by high-performance liquid 
chromatography (HPLC) before use. Preclamol (S-(-)-PPP), ethyl-
enediaminetetraacetic acid (EDTA), HPLC standards and other 
reagents were purchased from Sigma/RBI (Steinheim, Germany).
[3H]-DA Synthesis
Protocols for animal handling were previously approved by the 
Ethics Committee for Human and Animal Research (Universitat 
Autònoma de Barcelona) in accordance with the European 
Communities Council Directive of 24 November 1986(86/609/
EEC). The procedure used was previously described (Gonzalez-
Sepulveda et al., 2013). Male Sprague-Dawley rats of 200 to 250 g 
(Servei d’Estabulari, Universitat Autonoma de Barcelona, Spain) 
were killed by decapitation between 10:00 and 11:00 am. Brains 
were taken out immediately and chilled in modified Krebs-
Ringer-bicarbonate medium with the following composition: 
120 mM NaCl, 0.8 mM KCl, 2.6 mM CaCl2, 0.67 mM MgSO4, 1.2 mM 
KH2PO4, 27.5 mM NaHCO3, and 10 mM glucose, pH 7.4, saturated 
with 95% O2 / 5% CO2. In a 4ºC room, striata (including nucleus 
accumbens) were dissected and sliced using a McIlwain tis-
sue chopper to obtain minces with a shape that approximates 
cubes of 0.3 × 0.3 mm/side. Minces were suspended in the same 
medium and washed by centrifugation and resuspension to 
remove cell debris. Tissue minces were distributed into 2-mL 
polypropylene tubes and preincubated for 2 hours at 37°C in an 
Eppendorf Thermomixer under 95% O2 / 5% CO2 atmosphere. ARI, 
QUIN, S-(-)-PPP, or vehicle were added at the latest 10 minutes of 
preincubation. Then ring-labeled [3, 5- 3H]-L-tyrosine (40–60 Ci/
mmol) was added to all samples (final concentration of 0.12 μM), 
and incubation continued for 10 minutes more to synthesize 
[3H]-DA. A depolarizing condition was obtained by increasing the 
K+ in the Krebs buffer by adding concentrated KCl. This depolar-
izing medium was added 10 minutes before ARI or QUIN. When 
the D2 antagonist sulpiride was used, it was added 10 minutes 
before ARI or QUIN. The synthesis was stopped by the addition 
of a deproteinizing solution containing trichloroacetic acid and 
100 nmol internal standard DA per tube. Blank tubes contained 
deproteinizing solution prior to addition of [3H]-tyrosine and 
were kept ice-cold throughout. All samples were homogenized 
in a Dynatech/Sonic Dismembrator (Dynatech Labs, Chantilly, 
VA). An aliquot was taken for protein quantification by the Lowry 
method to take into account the variability of tissue amounts in 
each tube. Tissue homogenates were then centrifuged (12,000 g, 
10 minutes, 4°C), and supernatants were recovered for [3H]-DA 
purification by HPLC-UV.
The chromatographic system consisted of a reverse-phase 
C18 column (Tracer Extrasil ODS2, 5-μm particle size, 25 x 0.46 cm; 
Teknokroma, Spain) and an ion-pair mobile phase made of 
100 mM sodium phosphate buffer, 1 mM EDTA, and 0.75 mM 
octanesulfonic acid plus 12 % (vol/vol) methanol at pH 5. Flow 
rate was 1 mL/min. Internal standards were detected by UV 
285 nm. Radiolabelled and endogenous tyrosine and DA were 
undetectable by UV absorbance. Recovery of the internal stand-
ard was quantified in each sample (internal/external standard 
peak area). DA fractions were collected in scintillation vials, 
mixed with Optiphase HiSafe III cocktail, and [3H]-DA was quan-
tified in a liquid scintillation counter. Disintegrations per minute 
(dpm) obtained were corrected by DA internal standard recovery, 
dpm in blank samples, and protein content in each incubated 
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tube. Results were expressed as percentage vs control samples 
in the same experiment. Concentration-response curves were 
obtained after normalization to percent of controls in the same 
experiment, pooling of data, and nonlinear fit to sigmoidal dose 
response. The concentration curve of ARI in 2 mM K+ was best 
fitted to a 2-site competition curve.
Results
10 nM ARI Inhibits DA Synthesis through D2-Like 
Receptors under 2 mM K+ (Basal Conditions)
Activation of D2 receptors can inhibit DA synthesis in dopa-
minergic neurons in rat brain striatum. To confirm this, the 
well-known D2 receptor agonist quinpirole (QUIN) was used as 
a standard reference. Under 2 mM K+ (basal condition), QUIN 
decreased DA synthesis in a dose-dependent manner. As shown 
in Figure 1a, QUIN effects followed a 1-site model with the fol-
lowing parameters: Emax = 47.8 ± 0.42%; EC50 = 11.4 nM. This 
effect was totally blocked by the selective D2 receptor antagonist 
sulpiride (data not shown).
Under the same experimental conditions, we obtained the 
concentration-response curve of ARI on the inhibition of DA 
synthesis shown in Figure 1b. Unlike the dose-response curve 
of QUIN, this curve best fitted with a 2-site model with the 
following parameters: Emax = 69 ± 0.43%, EC501 = 0.93 nM, and 
EC502 = 0.21 µM (Table 1). Compared with the QUIN dose curve, 
we made the hypothesis that only the first part of the ARI dose-
response curve was due to its effects on D2 autoreceptors. To 
test this hypothesis, the typical selective D2 receptor antagonist 
sulpiride was applied to block D2 receptors. Sulpiride at 1  μM 
fully eliminated the inhibitory effect of ARI at 10 nM on DA syn-
thesis, which was consistent with our hypothesis (Figure 2a). In 
addition, QUIN failed to make a concentration-related response 
when added to the incubations 10 minutes after ARI 10 nM, 
as shown in Figure  2b. The comparisons between the 2 dose-
response curves of QUIN (one in the absence and the other in 
the presence of ARI 10 nM; Figure 2b) indicate that the D2 auto-
receptors have already been activated by ARI 10 nM. These data 
strengthen our hypothesis that low doses (≤100 nM) of ARI 
inhibit DA synthesis due to its action on D2-like receptors. To 
further address this issue, we examined whether the effects of a 
higher concentration of ARI (1 μM) could be blocked by sulpiride. 
Sulpiride (1 μM) partially blocked the effect of 1 µM ARI (from 
−50% to −32%; Figure 2c), but could not eliminate it completely. 
Thus, it is likely that micromolar concentrations of ARI inhibit 
DA synthesis through D2 and non-D2 mediated mechanisms.
ARI Failed to Activate D2 Autoreceptors under 15 mM 
K+ (Stimulated Conditions)
Increasing the potassium concentration in Krebs buffer from 
2 to 15 mM increased the amount of DA released, as expected. 
In preliminary experiments, the percent of newly synthesized 
[3H]-DA released to the medium under 2 mM K+ was 1.13 ± 0.95% 
(mean ± SD, N = 23 incubations) while under 15 mM K+ was 
7.5 ± 3.0% (N = 38 incubations). This led to a 6.6-fold increase in DA 
released. The increased concentrations of extracellular DA may 
facilitate its interaction with D2 autoreceptors. Previous reports 
have shown that the dopaminergic tone played a very impor-
tant role in evidencing the agonist property of ARI (Iñiguez et al., 
2008). Similarly, in our present study, we also observed different 
effects of ARI under different extracellular DA concentrations, 
which could also represent differences in the dopaminergic 
Figure 1. Concentration-response curve of quinpirole (QUIN) (a) and aripiprazole (ARI) (b) on the inhibition of dopamine (DA) synthesis in nonstimulated rat brain 
striatal minces (basal condition: 2 mM K+). Experimental design is shown in the time bar under the graph. Data represent the means ± SEM of N incubations indicated 
over the symbols. *P < .05, **P < .01, and ***P < .001 vs control (1-way ANOVA followed by Bonferroni’s test). Data were fitted to a sigmoidal dose-response (a) or a 2-site 
competition (b) curve. Parameters obtained are listed in Table 1.
Table 1. Parameters of Quinpirole, Aripiprazole, and S-(-)-PPP Inhi-
bition of Rat Brain [3H]-Dopamine Synthesis under Basal (2 mM K+) 
or Stimulated (15 mM K+) Conditions Representing Low- and High-
Dopaminergic Tone, Respectively
2 mM K+ 15 mM K+
Quinpirole
 IC50, nM 11 9.3
 Emax, % 49 39
Aripiprazole
 IC50 (1st/2nd  
component)
0.93 nM / 0.21 µM 68 nM
 Emax (1st / 2nd  
component), %
41/69 17
Preclamol (S-(-)-PPP)
 IC50, nM 0.11 0.051
 Emax, % 34 31
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tone (Table 1; Figure 3). Under 15 mM potassium conditions, ARI 
failed to inhibit DA synthesis at doses <10 μM (Figure 3b). We 
also measured the effect of QUIN under the same situation. As 
a typical D2 agonist, QUIN acted as a stable agonist under both 
conditions, as the dose-response curve of QUIN under 15 mM 
K+ was quite similar with the curve under 2 mM K+ (Figures 
1a and 3a), and the parameters for the 2 curves did not differ 
much either (Table  1). The reason why ARI failed to stimulate 
D2 autoreceptors in the depolarizing conditions could be either 
because ARI failed to bind to D2 receptors in the presence of the 
high concentration of DA or because ARI managed to bind but 
failed to stimulate D2 receptors more efficiently than DA, behav-
ing like an antagonist. To determine the reason, we treated the 
brain minces with both ARI and QUIN and observed that 10 nM 
ARI could totally eliminate the effects of QUIN at either 10 or 
100 nM (Figure 4). These results prove that ARI binds D2 receptors 
under these conditions but behaves as an antagonist under high 
dopaminergic tone. This result is fully consistent with a high 
affinity and low efficacy of ARI for the stimulation of D2 recep-
tors. Moreover, in the presence of 15 mM K+, 10 nM ARI tended to 
increase DA synthesis (Figure 4), as it would be expected for an 
antagonist of K+-released DA. To further characterize the influ-
ence of K+ in the properties of ARI, we gradually increased K+ 
concentrations from 2 to 15 mM K+ to increase the probability 
of DA release and tested the agonism elicited by 100 nM ARI. We 
found that under a 8-mM K+ threshold, ARI had agonist effects 
(Figure 5). These effects appeared full or partial depending on 
K+ concentrations and were clearly lost at higher K+. It seems 
likely that a higher extracellular DA concentration rendered 
ARI unable to stimulate D2 receptors more efficiently than the 
endogenous neurotransmitter, although alternative effects of 
depolarization on membrane environment cannot be ruled out 
(Sahlholm et al., 2011).
Comparison of the Effects of ARI with the Partial 
Agonist Preclamol (S-(-)-PPP)
Preclamol (S-(-)-PPP) has been extensively characterized as a 
D2 receptor partial agonist (Clark et al., 1985; Lathi et al., 1998; 
Tadori et  al., 2005). To assess whether the effects of ARI were 
unique to this compound or shared with other D2 partial ago-
nists, we assayed the effects of S-(-)-PPP on DA synthesis under 
Figure 2. Inhibition of dopamine (DA) synthesis by 10 nM aripiprazole (ARI) is mediated by D2 receptors. a, Striatal minces were incubated with sulpiride (1 μM) and ARI 
(10 nM) either alone or together under a 2-mM K+ condition. Sulpiride 1 µM could totally eliminate the effect of ARI at 10 nM. b, Concentration-response curve of quin-
pirole (QUIN) in the presence of 10 nM ARI under a 2-mM K+ condition. C, Sulpiride at 1 μM only partially blocks the inhibitory effect of ARI at 1 μM. Striatal minces were 
incubated under 2 mM K+. Experimental design is shown in a time bar under each graph. Data represent the means ± SEM of N incubations indicated by the symbols 
or inside bars. &P < .001 vs control, #P < .001 vs group treated with both ARI 10 nM and sulpiride 1 μM; *P < .05 and ***P < .001 vs group treated in the absence of ARI at the 
same dose. c, Statistical difference between both ARI-treated groups is expressed by a connecting line (1-way ANOVA followed by Bonferroni’s test).
Figure 3. Concentration-response curve of quinpirole (QUIN) (a) and aripiprazole (ARI) (b) on the inhibition of dopamine (DA) synthesis in stimulated rat brain striatal 
minces (high-dopaminergic tone condition: 15 mM K+). Experimental design is shown in the time bar under each graph. Data represent the means ± SEM of N incuba-
tions indicated by the symbols. *P < .05, **P < .01, and ***P < .001 vs control (1-way ANOVA followed by Bonferroni’s test). Data were fitted to a sigmoidal dose-response 
curve. Parameters obtained are listed in Table 1.
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2 and 15 mM K+ conditions. We found that S-(-)-PPP did inhibit 
DA synthesis quite similarly in both situations (Figure 6a and b), 
with maximal effects (−34 and −31%, respectively) smaller than 
those of ARI or QUIN. Although such small maximal effects are 
consistent with literature data on S-(-)-PPP, the shape of the con-
centration response curve appeared biphasic, with significant 
decreases of DA synthesis at 1 nM and 1 µM and some nonsig-
nificant points at the high nanomolar range and 10 µM as well 
(Figure 6). As the reported affinity of S-(-)-PPP for D2 receptors is 
in the high-nanomolar/low-micromolar range (Clark et al., 1985; 
Burris et al., 2002; Tadori et al., 2005), we were curious about the 
1 nM S-(-)-PPP significant effects. We found that the decrease in 
DA synthesis elicited by 1 nM S-(-)-PPP was completely reversed 
by 100 nM sulpiride (Figure  6c). Thus, it seems likely that S-(-
)-PPP elicits dual effects on DA synthesis quite different from 
those previously observed with ARI.
Discussion
In the present paper, we show that ARI actions on native D2-
like autoreceptors in rat brain presynaptic dopaminergic termi-
nals can be those of an agonist or an antagonist, depending on 
whether the experimental conditions mimic low or high dopa-
minergic tone. These results are consistent with the well-known 
low activity of ARI to stimulate D2 receptors that is characteristic 
of a partial agonist when compared with DA. However, we must 
note that important differences were found between ARI and 
preclamol (S-(-)-PPP), another well-characterized D2 receptor 
partial agonist that seems to work differently. The strength of 
these results is that we use an approach that can be considered 
more physiologically relevant than previous articles in receptor-
transfected cells. First, D2 receptors involved were neuronal. 
Second, DA competing with ARI was released by K+ stimula-
tion of brain tissue ex vivo. And finally, the response measured 
is [3H]-DA synthesis, a specific process of catecholaminergic 
neurons, mostly dopaminergic in the striatum. However, these 
strengths bring together the challenge of the correct interpreta-
tion of results obtained in this complex tissue sample, where 
other receptors and brain terminals and other cells are also 
naturally present.
Presynaptic D2 receptors are thought to be the D2S subtype 
compared with the full-length D2L subtype (Usiello et al., 2000). 
Previous work by Kikuchi et al. (1995) suggested that the agonist 
or antagonist properties of ARI were dependent on the presyn-
aptic vs postsynaptic localization of D2 receptors, respectively. 
However, here we show that ARI can show both agonist and 
antagonist properties at the same presynaptic location control-
ling DA synthesis. This indicates that the subtype of D2 recep-
tor involved does not explain the switch in the behavior of ARI. 
In agreement, later work by Kikuchi’s group (Tadori et al., 2005, 
2009, 2011a, 2011b) found that ARI can be agonist and antago-
nist on recombinant human D2S receptors, depending on the 
level of receptor expression and competing DA. Thus, our results 
validate in brain tissue the later hypothesis of these authors. 
Presynaptic D2-like receptors can be fully stimulated by ARI pro-
vided that competing DA is maintained at low levels. In contrast, 
during nerve terminal release of DA, ARI behaves as an antago-
nist because of its lower efficacy to stabilize the active confor-
mation of D2 receptors compared with DA. The subtype of D2-like 
receptors controlling DA synthesis likely is the D2S, although a 
minor contribution of D3 receptors or postsynaptic D2 receptors 
cannot be completely ruled out (Usiello et  al., 2000; Anzalone 
et al., 2012).
Previous work also showed that the intrinsic activity of D2 
partial agonists seems to depend on receptor reserve (Meller 
et al., 1987; Burris et al., 2002). A partial agonist like ARI might 
stabilize D2 receptors in a conformation that activates G pro-
teins only for short periods or with low efficacy, leading to 
higher dissociation constants of the receptor-G protein com-
plex. As a consequence, it may need to occupy significantly 
more receptors than the full agonist QUIN to reach a similar 
maximal agonist effect. These “extra” receptors available for 
the agonist properties of ARI can come from the so-called 
receptor reserve (Figure 7). A higher receptor reserve has been 
Figure 4. 10 nM aripiprazole (ARI) blocks quinpirole (QUIN) inhibition of dopa-
mine (DA) synthesis under 15-mM K+ conditions. Minces were treated with ARI 
(10 nM) and QUIN (10 and 100 nM) either alone or together. Experimental design 
is shown in the time bar under the graph. Data represent the means ± SEM of N 
incubations indicated inside the bars. *P < .05 vs blank control. #P < .05 and &P < .05 
in the 2 groups of connected bars (1-way ANOVA followed by Bonferroni’s test).
Figure 5. Titration of aripiprazole (ARI) effects on dopamine (DA) synthesis vs 
increasing K+ concentrations. ARI (100 nM) behaved as an agonist with K+ con-
centrations up to 6 mM in our brain minces incubations. Experimental design 
is shown in the time bar under the graph. Data shown represent means ± SEM 
of N incubations indicated over the symbols, normalized to the respective con-
trol group under the same K+ concentration (not show in the graph). *P < .05 and 
***P < .001 vs control group under the same K+ concentration (1-way ANOVA fol-
lowed by Bonferroni’s test).
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hypothesized for presynaptic D2 receptors compared with 
postsynaptic D2 receptors (Meller et al., 1987). Therefore, a par-
tial agonist like ARI will appear to have higher intrinsic activity 
at presynaptic D2 receptors vs postsynaptic D2 receptors due 
to receptor reserve. This assumption fits experimental data 
(Kikuchi et  al., 1995; Burris et  al., 2002). Nevertheless, a high 
receptor reserve is necessary but not sufficient for ARI to show 
its agonist properties: a low dopaminergic tone is also required. 
Previous papers showing agonist effects of ARI on DA synthe-
sis required a low dopaminergic tone, achieved by reserpine 
or gamma-butyrolactone treatment to animals (Kikuchi et al., 
1995; Iñiguez et  al., 2008). Reserpine depletes DA stores, and 
gamma-butyrolactone is considered a nerve impulse inhibitor 
preventing DA release. In our work, an interruption of nerve 
impulses takes place at slicing striatal tissue by cutting off 
nerve endings from dopaminergic cells bodies. Therefore, our 
basal conditions (2 mM K+) may well be considered relatively 
similar to gamma-butyrolactone in that they produce a low 
dopaminergic tone, where only 1% of newly synthesized [3H]-
DA is released to the medium. Accordingly, we may wonder 
whether ARI is actually able to act as an agonist in vivo, where 
dopaminergic tone might be fluctuating within a range difficult 
to define. Indeed, human results suggest that ARI has actions 
consistent with agonism on D2 receptors controlling prolactin 
release, in contrast with most antipsychotics (Safer et al., 2013). 
Whether ARI acts as a D2 agonist on nerve terminals involved 
in psychosis remains speculative, but it is worth considering, 
as it led to its discovery (Kikuchi et al., 1995). Beneficial effects 
of selective dopaminergic autoreceptor agonists have been 
postulated for the treatment of psychosis (Tamminga, 2002). 
Figure 6. The effects of the D2 partial agonist preclamol (S-(-)-PPP) differ from those of aripiprazole (ARI) previously shown. Concentration-response curves of S-(-)-
PPP on the inhibition of dopamine (DA) synthesis in (a) nonstimulated (basal condition: 2 mM K+) or (b) stimulated rat brain striatal minces (high-dopaminergic tone 
condition: 15 mM K+). c, The effect of 1 nM S-(-)-PPP is completely blocked by sulpiride (100 nM). Experimental design is shown in the time bar under the graph. Data 
represent the means ± SEM of N incubations indicated over the symbols inside bars. *P < .05 and ***P < .001 vs control. &P < .001 vs control, #P < .001 vs group treated with 
both S-(-)-PPP 1 nM and sulpiride 100 nM (1-way ANOVA followed by Bonferroni’s test). Data were fitted to a sigmoidal dose-response curve. Parameters obtained are 
listed in Table 1.
Figure 7. Hypothetical model explaining the actions of partial agonists aripiprazole (ARI) and preclamol ((-)PPP) and the full agonist quinpirole (QUIN) on dopamine 
(DA) synthesis. Both partial agonists would mobilize the receptor reserve, as a difference with the full agonist quinpirole. The 2 partial agonists would, however, sta-
bilize different conformations of the D2 receptors, leading to functional selectivity for signaling proteins. G1 and G2 could be different G proteins or other signaling 
molecules competing for binding to the active receptor. ARI would stimulate G1 only if a low-dopaminergic tone is present, since DA more efficiently activates D2 
receptors than ARI.
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However, if a high dopaminergic tone is expected during psy-
chosis, the antagonistic action of ARI on both pre- and postsyn-
aptic D2 receptors will more likely prevail and correlate with its 
antipsychotic effects. On the other hand, the postulated “DA 
stabilization” elicited by ARI would only make sense on pre-
synaptic D2 receptors, which have sufficient receptor reserve 
to account for ARI agonist and antagonist properties. The lower 
receptor reserve of postsynaptic D2 receptors would only allow 
antagonist-like effects of ARI, based on the lack of sufficient 
G protein activation. Therefore, postsynaptic “DA stabilization” 
would not be possible unless alterations in receptor sensitivity 
or functional selectivity add new levels of complexity to the 
postsynaptic actions of ARI (Meller et al., 1987; Mailman, 2007; 
Mailman and Murphy, 2010).
The difference in maximal effects between ARI and S-(-)-PPP 
cannot be explained solely by the receptor reserve hypothesis. 
S-(-)-PPP usually shows higher intrinsic activity than ARI under 
several assays (Burris et al., 2002; Tadori et al., 2005; Kehne et al., 
2008), so we were surprised by the lower maximal effect of S-(-
)-PPP compared with ARI (−34% vs −41%, respectively, at 2 mM 
K+ (Figure  6a; Table  1). Similarly, literature binding data show 
that the conformation of D2 receptors stabilized by ARI might be 
closer to that of a typical antagonist compared with that stabi-
lized by S-(-)-PPP (Burris at al., 2002; Urban et al., 2007b; but see 
also Shapiro et al., 2003). Intrinsic activity of D2 receptor partial 
agonists depends on the assay used (Kehne et al., 2008), which 
could be due to functional selectivity vs several intracellular cas-
cades and their respective amplification mechanisms (Kenakin 
and Morgan, 1989). The fact that in our functional assay ARI was 
more efficient than S-(-)-PPP may be an indication of preferred 
functional selectivity of ARI vs the transduction pathway inhib-
iting DA synthesis. In fact, Mottola et al. (2002) found evidence 
of D2 agonists having the opposite functional selectivity, with 
poor effects on D2-controlled DA synthesis, which gives support 
to the functional selectivity hypothesis. In addition, we were 
also surprised by the shape of the concentration curve S-(-)-PPP, 
which suggests a complex interaction with receptors controlling 
DA synthesis. The rise of extracellular DA elicited by 15 mM K+ 
does not seem to affect it, which is similar to QUIN, but not to 
ARI. Although a detailed study of S-(-)-PPP effects exceeds the 
scope of this paper, its effects seem to be D2 mediated (Figure 6c; 
but see Largent et  al., 1987). Alternative explanations can be 
considered, such as better oligomerization of some receptor 
conformations than others, although at present this would be 
highly speculative (Navarro et al., 2013).
When DA release was stimulated by 15 mM K+, nanomolar 
concentrations of ARI did not decrease [3H]-DA synthesis like 
QUIN or S-(-)-PPP, but instead they clearly blocked QUIN action, 
behaving as an antagonist. In addition, in the absence of QUIN, 
we observed a slight tendency to increase [3H]-DA synthesis in 
samples treated with ARI. This could reveal ARI antagonism of 
K+-released endogenous DA stimulating D2 receptors. We do not 
know how much of endogenous DA was released by 15 mM K+ or 
the concentrations of extracellular DA achieved, because these 
values would be hard to obtain within the same experiment in 
our conditions. We know from preliminary experiments that 
the percent of newly synthesized [3H]-DA released by 15 mM K+ 
increases by 6.6-fold on average compared with 2 mM K+. We 
hypothesized that this K+ stimulation would model a higher 
dopaminergic tone in rat brain minces ex vivo, but we must 
acknowledge that membrane depolarization may also have 
additional effects on D2 receptor conformation and interactions 
with signaling molecules (Sahlholm et al., 2011). Furthermore, 
any comparison of our results with dopaminergic tone in 
human schizophrenics would be speculative. Nevertheless, we 
observed a remarkable switch of ARI behavior from agonist to 
antagonist by increasing K+. Therefore, our method could be 
useful for future pharmacological research of newer D2/3-based 
antipsychotics with low liability of side effects based on clini-
cal experience with ARI. New compounds like brexpiprazole or 
cariprazine are being clinically tested. Additional D2 partial ago-
nists already exist, but ARI has been the most clinically success-
ful so far. An important question to consider on this issue is the 
degree of intrinsic efficacy of a partial agonist that is optimal for 
the best antipsychotic effects (Tamminga, 2002). ARI is consid-
ered to have low intrinsic efficacy; that is, its activity is closer 
to that of an antagonist than to that of an agonist. Previous 
D2 partial agonists tested may have failed to display the ade-
quate intrinsic activity for antipsychotic clinical effects (Lathi 
et al., 1998; Tadori et al., 2005; Natesan et al., 2010). An impor-
tant additional question is whether there is a clear relationship 
between D2 partial agonism and low liability of extrapyramidal 
side effects. Two main hypotheses are currently being consid-
ered. First, D2 occupancy by antagonists might have a threshold 
over which extrapyramidal effects would appear. And second, 
transient D2 blockade would elicit less extrapyramidal side 
effects than continuous blockade (Seeman, 2002). Surprisingly, 
ARI occupancy of D2 receptors at clinically relevant doses has 
been shown to be well above the threshold considered for other 
antipsychotics, and ARI is not relatively fast at dissociating from 
D2L receptors (Kuroki et  al., 2002; Seeman, 2005; Maggio and 
Millan, 2010). This suggests that ARI action on D2 conformation 
might contribute to low liability of extrapyramidal effects. The 
low efficacy of ARI - D2 - G protein activation might not elicit 
significant postsynaptic responses, but it may allow a higher D2 
receptor occupancy than other antipsychotics without produc-
ing extrapyramidal side effects.
Our determination of [3H]-DA synthesis in brain tissue ex 
vivo is methodologically faster than classical DOPA accumula-
tion in vivo. We obtained 24 incubations of brain minces from the 
striata of a single rat. QUIN and ARI IC50 values obtained were 
very similar to those reported in the literature (Table 1). QUIN 
reached its maximal effect (48% decrease) at 100 nM. In contrast, 
the maximal effect of ARI was a 68% decrease at the concentra-
tion 1  µM, with a curve best adjusted to 2 sites. ARI not only 
has affinity for D2 receptors, it also has significant affinity for 
a large number of other G-protein coupled receptors, such as 
serotonergic, adrenergic, and histaminergic receptors (Shapiro 
et al., 2003). The low-affinity effect of ARI on [3H]-DA synthesis 
could be related to actions on serotonin or other receptors, as it 
has a higher IC50 than D2-mediated effects (Table 1) and it was 
not blocked by 1 μM sulpiride (Figure 2c). The selective 5-HT1A/7 
receptor agonist R(+)-8-OH-DPAT attenuates amphetamine-
induced DA synthesis in rat striatum (Kuroki et al., 2000), and 
also other agonists of 5-HT1A receptors inhibit tyrosine hydroxy-
lase in rat striatum (Johnson et al., 1996). We must note, how-
ever, that 5-HT1A receptors are considered as somatodendritic 
and unlikely present in dopaminergic terminals. The seroton-
ergic actions of ARI deserve further investigation, as they could 
contribute to its unique antipsychotic effects (Jordan et al., 2002; 
Shapiro et al., 2003; Bortolozzi et al., 2007). Here in our study, the 
non-D2 receptor effect of ARI on the inhibition of DA synthe-
sis might be related with serotonin 5-HT1A/7, 5-HT2C receptors, or 
receptors for additional neurotransmitters (DiMateo et al., 2001; 
Shapiro et al., 2003), but further studies are needed to confirm 
these hypotheses. The low presence of serotonergic receptors 
in dopaminergic terminals open the possibility that the non-D2 
effects of ARI on DA synthesis are indirectly mediated by GABA 
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or glutamate terminals also present in our minces of striatal tis-
sue. This effect does not disappear under the 15 mM K+ condi-
tion, which also differentiates it from D2-mediated effects.
In conclusion, we observed different properties of ARI under 
different levels of dopaminergic tone in the surrounding milieu: 
agonist under low dopaminergic tone and antagonist under a 
relatively higher dopaminergic tone elicited by increasing K+ 
concentrations. This can be based on the low activity of ARI as 
agonist and the high receptor reserve of presynaptic D2 autore-
ceptors, but the functional selectivity hypothesis must be taken 
into consideration, as it has different effects than S-(-)-PPP. In 
contrast, the D2 receptor full agonist QUIN acted as a clear ago-
nist under both conditions. We also observed an effect of ARI at 
higher concentrations that is not apparently D2 mediated. These 
results indicate that ARI effects on presynaptic D2-like receptors 
in brain tissue have unique properties that clearly differentiate 
it from other traditional antipsychotics.
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